Literature DB >> 16908131

The tumour suppressor hSNF5/INI1 controls the differentiation potential of malignant rhabdoid cells.

Patricia Albanese1, Marie-France Belin, Olivier Delattre.   

Abstract

Malignant rhabdoid tumours (MRT) are highly aggressive cancers of early childhood that arise in different organs or tissues. The unifying criterion for these tumours is the presence of inactivating mutations of the hSNF5/INI1 tumour suppressor gene which encodes a core subunit of the chromatin remodelling SWI/SNF complex. Using a variety of markers we analysed the phenotypic traits of MON and DEV cell lines derived respectively from an undifferentiated abdominal MRT and from a brain MRT. DEV cells express spontaneously a wide range of neural and glial markers. It can be induced to differentiate into the neural lineage following hSNF5/INI1 expression with appearance of neurite processes, strong increase of neural markers and decrease of glial markers. A less pronounced neural differentiation is also observed with MON cells, which possess more primitive polyphenotypic features with positivity for markers from the three embryonic layers. Finally, we show that the neural differentiation of rat PC12 cells in the presence of nerve growth factor (NGF) is strongly impaired when hSNF5/INI1 expression is inhibited by RNA interference. Altogether these results indicate that hSNF5/INI1 is an essential subunit for SWI/SNF-dependant induction of neural differentiation programs. Further experiments should enable documentation of whether it provides instructive or permissive signals for differentiation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16908131     DOI: 10.1016/j.ejca.2006.03.028

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  11 in total

1.  Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2.

Authors:  Sarah K Knutson; Natalie M Warholic; Tim J Wigle; Christine R Klaus; Christina J Allain; Alejandra Raimondi; Margaret Porter Scott; Richard Chesworth; Mikel P Moyer; Robert A Copeland; Victoria M Richon; Roy M Pollock; Kevin W Kuntz; Heike Keilhack
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-25       Impact factor: 11.205

2.  Reexpression of hSNF5 in malignant rhabdoid tumor cell lines causes cell cycle arrest through a p21(CIP1/WAF1)-dependent mechanism.

Authors:  Yasumichi Kuwahara; Aubri Charboneau; Erik S Knudsen; Bernard E Weissman
Journal:  Cancer Res       Date:  2010-02-23       Impact factor: 12.701

Review 3.  What is new in epithelioid soft tissue tumors?

Authors:  Abbas Agaimy
Journal:  Virchows Arch       Date:  2019-11-04       Impact factor: 4.064

4.  Pediatric rhabdoid tumors of kidney and brain show many differences in gene expression but share dysregulation of cell cycle and epigenetic effector genes.

Authors:  Diane K Birks; Andrew M Donson; Purvi R Patel; Alexandra Sufit; Elizabeth M Algar; Christopher Dunham; B K Kleinschmidt-DeMasters; Michael H Handler; Rajeev Vibhakar; Nicholas K Foreman
Journal:  Pediatr Blood Cancer       Date:  2013-02-04       Impact factor: 3.167

5.  Rhabdoid tumor: gene expression clues to pathogenesis and potential therapeutic targets.

Authors:  Samantha Gadd; Simone Treiger Sredni; Chiang-Ching Huang; Elizabeth J Perlman
Journal:  Lab Invest       Date:  2010-03-08       Impact factor: 5.662

6.  Renal medullary carcinoma: molecular, immunohistochemistry, and morphologic correlation.

Authors:  Qingyan Liu; Susanna Galli; Ramaprasad Srinivasan; William Marston Linehan; Maria Tsokos; Maria J Merino
Journal:  Am J Surg Pathol       Date:  2013-03       Impact factor: 6.394

7.  Epithelioid leiomyosarcoma with rhabdoid features.

Authors:  Gülnur Yorulmaz; Gülgün Erdogan; Hadice Elif Pestereli; Burhan Savas; Fatma Seyda Karaveli
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

8.  Establishment of atypical-teratoid/rhabdoid tumor (AT/RT) cell cultures from disseminated CSF cells: a model to elucidate biology and potential targeted therapeutics.

Authors:  Aru Narendran; Lucas Coppes; Aarthi Jayanthan; Michael Coppes; Bijan Teja; Delphine Bernoux; David George; Douglas Strother
Journal:  J Neurooncol       Date:  2008-07-24       Impact factor: 4.130

9.  Comprehensive Analysis of Chromatin States in Atypical Teratoid/Rhabdoid Tumor Identifies Diverging Roles for SWI/SNF and Polycomb in Gene Regulation.

Authors:  Serap Erkek; Pascal D Johann; Martina A Finetti; Yiannis Drosos; Hsien-Chao Chou; Marc Zapatka; Dominik Sturm; David T W Jones; Andrey Korshunov; Marina Rhyzova; Stephan Wolf; Jan-Philipp Mallm; Katja Beck; Olaf Witt; Andreas E Kulozik; Michael C Frühwald; Paul A Northcott; Jan O Korbel; Peter Lichter; Roland Eils; Amar Gajjar; Charles W M Roberts; Daniel Williamson; Martin Hasselblatt; Lukas Chavez; Stefan M Pfister; Marcel Kool
Journal:  Cancer Cell       Date:  2018-12-27       Impact factor: 31.743

10.  Multi-tyrosine kinase inhibitors in preclinical studies for pediatric CNS AT/RT: Evidence for synergy with Topoisomerase-I inhibition.

Authors:  Aarthi Jayanthan; Delphine Bernoux; Pinaki Bose; Karl Riabowol; Aru Narendran
Journal:  Cancer Cell Int       Date:  2011-12-29       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.